EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CRSP: Crispr Therapeutics Ag

28 Oct 25 10:01
LAST:

64.08

CHANGE:
 1.65		OPEN:
65.52		HIGH:
66.00		ASK:
20.25		VOLUME:
180.1K
CHG(%):
2.51		PREV:
65.73		LOW:
63.63		BID:
17.88		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Oct 2565.5266.0063.6364.08180.1K
27 Oct 2567.1367.7364.1065.723.0M
24 Oct 2568.2168.7166.8567.611.34M
23 Oct 2566.6167.4965.4567.211.55M
22 Oct 2570.1070.7464.8066.523.19M
21 Oct 2573.7975.0671.0072.321.87M
20 Oct 2571.1374.4370.8073.972.69M
17 Oct 2567.5569.5767.0069.152.01M
16 Oct 2570.0071.5267.8268.432.58M
15 Oct 2570.0173.0969.8071.822.37M

COMPANY PROFILE

Name:Crispr Therapeutics Ag
About:CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Sector:Healthcare
Industry:Biotechnology
Address:Baarerstrasse 14, Zug, Switzerland, 6300
Website:https://www.crisprtx.com
CUSIP:H17182108
CIK:0001674416
ISIN:CH0334081137
FIGI:BBG00DBBGRX1
LEI:506700O6IRRIQLT3W370

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:66.173.3%
MA10:68.667.1%
MA20:69.839.0%
MA50:62.023.3%
MA100:57.8110.8%
MA200:48.8531.2%
RSI14:30.52 
WPR14:-100.00 
MTM14:-11.12
ROC14:-0.15 
ATR:4.52 
Week High:75.0617.1%
Week Low:63.630.7%
Month High:78.4822.5%
Month Low:61.5631.2%
Year High:78.4822.5%
Year Low:30.04113.3%
Volatility:27.61 

RECENT SPLITS

Date Ratio
19 Jul 2016333333-100000